1999: a time to re-evaluate AIDS vaccine strategies.
The field of AIDS vaccine development is in flux. Important new findings were reported in 1999 that led to a rethinking of AIDS vaccine strategies. We have been given the challenging task of providing an overview. Rather than attempting to provide a comprehensive summary, we will restrict our discussion to a few major topics, and we ask for understanding if we can only highlight.
Ruprecht
R M
RM
Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA. ruth_ruprecht@dfci.harvard.edu
Hofmann-Lehmann
R
R
Rasmussen
R A
RA
Vlasak
J
J
Xu
W
W
D016915:AIDS Vaccines / Q000096:biosynthesis; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control* / Q000821:virology; D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D001667:Binding, Competitive; D017353:Gene Deletion; D015754:Genes, nef / Q000235:genetics / Q000276:immunology; D006678:HIV / Q000235:genetics / Q000276:immunology; D006801:Humans; D009500:Neutralization Tests; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology; D014613:Vaccines, Attenuated / Q000096:biosynthesis
D016915:AIDS Vaccines; D000906:Antibodies; D014613:Vaccines, Attenuated